Molecular Features and Targeted Therapy in KRAS wild-type Pancreatic Cancer

KRAS mutation is the major oncogenic event in approximately 90% of pancreatic ductal adenocarcinomas. The subset of patients with KRAS wild-type pancreatic ductal adenocarcinomas represent a distinct subgroup with a higher frequency of actionable genomic alterations. In this review article, we aim at exploring the more frequent molecular alterations found among KRAS wild-type pancreatic ductal adenocarcinomas, their prognostic implications, as well as the potential targetable therapeutic options beyond cytotoxic chemotherapy for this unique subset of patients.